Literature DB >> 4994070

[Use of neutron activation analysis in the diagnosis and follow-up studies of Wilson's disease].

G Henke, H Möllmann, W Althoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4994070     DOI: 10.1007/bf01485434

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


× No keyword cloud information.
  11 in total

1.  Trace elements in human tissue. II. Adult subjects from the United States.

Authors:  I H TIPTON; M J COOK
Journal:  Health Phys       Date:  1963-02       Impact factor: 1.316

2.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

3.  The effects of B.A.L. in hepatolenticular degeneration.

Authors:  J N CUMINGS
Journal:  Brain       Date:  1951-03       Impact factor: 13.501

Review 4.  [10 years of penicillamine].

Authors:  T Werner; H M Weinmann
Journal:  Med Klin       Date:  1966-11-18

5.  [Determination of Cu by activation analysis in liver punctates in Wilson's disease].

Authors:  H Möllmann; G Henke; H Alfes
Journal:  Z Klin Chem Klin Biochem       Date:  1969-11

6.  [Physiology and pathology of copper metabolism].

Authors:  H Büechl; M Kludas
Journal:  Ther Ggw       Date:  1969-05

7.  Loss of taste during therapy with penicillamine.

Authors:  H R Keiser; R I Henkin; F C Bartter; A Sjoerdsma
Journal:  JAMA       Date:  1968-02-05       Impact factor: 56.272

8.  [On the course and therapy of a juvenile Wilson's disease case].

Authors:  P Wallauer; H Harbauer
Journal:  Dtsch Med Wochenschr       Date:  1967-06-30       Impact factor: 0.628

9.  [Long-term treatment of Wilson's disease with D-penicillamine. Report on 20 cases].

Authors:  J Lange
Journal:  Dtsch Med Wochenschr       Date:  1967-09-15       Impact factor: 0.628

10.  The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease).

Authors:  D DENNY-BROWN; H PORTER
Journal:  N Engl J Med       Date:  1951-12-13       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.